Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | PRCP | P42785 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 3/20 | 0.34 |
| ▸ | CEL | P19835 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5953469 | 0.81 | HTR1A (0.38) | HTR1AHTR7PRCPPTGS2CEL | |
| SCHEMBL5953649 | 0.81 | HTR1A (0.38) | HTR1AHTR7PRCPPTGS2HTR2C | |
| SCHEMBL4652090 | 0.79 | HTR1A (0.31) | HTR1AHTR7 | |
| SCHEMBL5953488 | 0.78 | CEL (0.33) | HTR1AHTR7HTR2CCEL | |
| SCHEMBL5953865 | 0.75 | HTR1A (0.40) | HTR1AHTR7PTGS2HTR2CCEL | |
| SCHEMBL31240954 | 0.73 | HTR2C (0.52) | HTR1AHTR7PTGS2HTR2CCEL | |
| SCHEMBL5954073 | 0.72 | BCHE (0.36) | CEL | |
| SCHEMBL31498318 | 0.71 | HTR1A (0.34) | HTR1AHTR7TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL4035804 | 0.69 | CYP2A6 (0.36) | — | |
| SCHEMBL30477217 | 0.69 | CYP2A6 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052620-A1 | Preparation of substituted indenes | BASELL POLYOLEFINE GMBH (DE) | 2006-03-09 | — | — | US | disclosed |
| EP-1492749-A1 | PREPARATION OF SUBSTITUTED INDENES | Basell Polyolefine GmbH (DE) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003084904-A1 | PREPARATION OF SUBSTITUTED INDENES | BASELL POLYOLEFINE GMBH (DE) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052620-A1 | Preparation of substituted indenes | INTS9, CYP1A2, INF2 | HTR1A 2748/4885HTR7 2787/4885PRCP 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.